
Recombinant Human Epidermal Growth Factor, Silver Sulfadiazine & Chlorhexidine Gluconate Cream

-
- Indicated for 1st & 2nd degree burns.
- Can also be used for minor cuts, abrasions, incisions & wounds.
Efficacy of SLVRGEN® in comparison with commercially available Silver sulfadiazine in healthy participants with superficial and partial thickness burn.

Duration of treatment | SLVRGEN® | Reference |
1 week | 87 (29%) | 22 (15%) |
2 week | 213 (71%) | 35 (23%) |
4 week | 300 (100%) | 89 (59%) |
6 week | — | 150 (100%) |

%TBSA | SLVRGEN® | Reference |
1 to 10 | 5 | 11 |
11 to 20 | 11 | 19 |
20 to 30 | 23 | 32 |
SLVRGEN® Safety Data
Percentage of adverse events between two treatment groups

Why SLVRGEN®?
The conventional SSD usage delays wound healing process by:1-3
- Absorption of silver from burn wounds leading to cytotoxicity
- Causing bacterial resistance
- Insufficient or delayed production of growth promoting factors and their receptors
Studies show that cytoprotective effect offered by EGF against SSD-exposed cell leads to reversal of impaired wound healing, early cell proliferation & epithelization.1
Parameters | SLVRGEN® | Silver Sulfadiazine | Colloidal Silver |
Composition
|
Recombinant human Epidermal Growth Factor + Silver Sulfadiazine + Chlorhexidine Gluconate | Silver Sulfadiazine + Chlorhexidine Gluconate
|
Colloidal Silver |
Pharmaceutical form | Topical cream | Topical cream | Topical gel |
Therapeutic indication | Indicated for 1st & 2nd degree burns. Can also be used for minor cuts, abrasions, incisions & wounds. | Burns, wound sepsis, lesions of the skin, wounds & injuries.
|
Burns, wounds & ulcers
|
Silver content | Silver sulfadiazine 1% w/w | Silver sulfadiazine 1% w/w | Colloidal silver 32 ppm |
Frequency of application | Reapplied at least every 24 hours | Multiple times a day | Multiple times a day |
Storage temperature | Stable at room temperature | Stable at room temperature. | Stable at room temperature |
Observation | The cytotoxic property of SSD in retarding the wound healing can be reversed with the addition of rhEGF.1,4
SLVRGEN® synergistically plays a vital role in controlling infection & also promoting fast wound healing. |
Adsorption of silver from burn wounds leads to impairment of dermal regeneration & decreases the mechanical strength of dermal tissue.1,5
|
Silver poisoning is a well-known issue.6 |
ppm, parts per million; w/w, weight by weight; As per several studies conducted on rhEGF & SSD.
References:
- Cho Lee, AR, et al. Reversal of silver sulfadiazine-impaired wound healing by epidermal growth factor. Biomaterials. 2005;26(22):4670-4676.
- Hidalgo E. Study of cytotoxicity mechanisms of silver nitrate in human dermal fibroblasts. Toxicol Lett. 1998;98(3):169-179.
- Poon VK. In vitro cytotoxity of silver: implication for clinical wound care. Burns. 2004;30(2):140-147.
- McCauley RL, et al. Cytoprotection of human dermal fibroblasts against silver sulfadiazine using recombinant growth factors. J Surg Res. 1994;56(4):378-84.
- White RJ , et al. Silver Sulphadiazine: A review of the evidence. Wounds UK.
- Niels Hadrup, et al. Oral toxicity of silver ions, silver nanoparticles and colloidal silver – A review. Regul Toxicol Pharmacol. 2014;68(1):1-7
Abridged Prescribing Information
SLVRGEN® is a registered trademark of Bharat Biotech. Manufactured by: Bharat Biotech. Marketed by: Anamay Biotech
©2019 Anamay Biotech. All rights reserved. MM/2019
For more details www.anamaybiotech.com